Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 3, 2009, Pages 480-487

  Kim, Nayoung ^a,b   Kim, Chung Hyun ^a   Ahn, Dong Won ^a   Lee, Kyoung Soo ^a   Cho, Soo Jeong ^a   Park, Ji Hyun ^a   Lee, Mi Kyoung ^a   Kim, Joo Sung ^a   Jung, Hyun Chae ^a   Song, In Sung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Akt; Apoptosis; Celecoxib; Gastric cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CELECOXIB; INDOMETACIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER; WESTERN BLOTTING;

EID: 63049088528     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05599.x     Document Type: Article

References (60)

1. Chan AT, Giovannucci EL, Meyerhardt JA et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008 134 : 21 8.
2. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 1997 11 : 234 47.
3. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996 7 : 203 5.
4. Hsu AL, Ching TT, Wang DS et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 2000 275 : 11 397 403.
5. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995 76 : 1116 19.
6. Thun MJ, Namboodiri MM, Calle EE et al. Aspirin use and risk of fatal cancer. Cancer Res. 1993 53 : 1322 7.
7. Langman MJ, Cheng KK, Gilman EA et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000 320 : 1642 6.
8. Akre K, Ekstrom AM, Signorello LB et al. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br. J. Cancer 2001 84 : 965 8.
9. Wang WH, Huang JQ, Zheng GF et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2003 95 : 1784 91.
10. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000 342 : 1946 52.
11. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest. 1997 100 : 1325 9.
12. Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000 157 : 729 35.
13. Leung WK, To KF, Ng YP et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer 2001 84 : 335 9.
14. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam. Clin. Pharmacol. 1996 10 : 1 17.
15. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999 18 : 7908 16.
16. Hu PJ, Yu J, Zeng ZR et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004 53 : 195 200.
17. Charalambous D, O'Brien PE. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J. Gastroenterol. Hepatol. 1996 11 : 307 10.
18. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 1997 3 : 1679 83.
19. Hanif R, Pittas A, Feng Y et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 1996 52 : 237 45.
20. Cho SJ, Kim N, Kim JS et al. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig. Dis. Sci. 2007 52 : 1713 21.
21. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002 2 : 489 501.
22. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004 9 : 667 76.
23. Korean Ministry of Health & Welfare. The Third National Health and Nutrition Examination Survey (KNHANES III) 2005. Gwacheon-si, Gyeonggi-do : Korean Ministry of Health & Welfare, 2006.
24. Arico S, Pattingre S, Bauvy C et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 2002 277 : 27 613 21.
25. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001 15 : 2742 4.
26. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002 62 : 2029 33.
27. Wu T, Leng J, Han C et al. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol. Cancer Ther. 2004 3 : 299 307.
28. Karin M, Cao Y, Greten FR et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002 2 : 301 10.
29. Ozes ON, Mayo LD, Gustin IA et al. NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature 1999 401 : 82 5.
30. Kane LP, Shapiro VS, Stokoe D et al. Induction of NF-kB by the Akt/PKB kinase. Curr. Biol. 1999 9 : 601 4.
31. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kB transcription factors. Oncogene 1999 18 : 6919 24.
32. Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cell and is required for PKB-mediated protein from apoptosis. Mol. Cell. Biol. 2001 21 : 5797 805.
33. Leng J, Han C, Demetris AJ et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003 38 : 756 68.
34. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999 13 : 2905 27.
35. Yamaguchi A, Tamatani M, Matsuzaki H et al. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J. Biol. Chem. 2001 276 : 5256 64.
36. Cross D, Alessi D, Cohen P et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995 378 : 785 9.
37. Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 2001 114 : 2903 10.
38. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997 9 : 231 41.
39. Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998 282 : 1318 21.
40. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999 96 : 857 68.
41. Lee BL, Lee HS, Jung J et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin. Cancer Res. 2005 11 : 2518 25.
42. Murakami D, Tsujitani S, Osaki T et al. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer 2007 10 : 45 51.
43. Nam SY, Lee HS, Jung GA et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 2003 111 : 1105 13.
44. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 2006 24 : 4309 16.
45. Lee BL, Kim WH, Jung J et al. Carcinogenesis. A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis 2008 29 : 44 51.
46. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk - where are we now? Nat. Clin. Pract. Cardiovasc. Med. 2005 2 : 290 300.
47. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005 352 : 1092 102.
48. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003 107 : 405 9.
49. Steffel J, Hermann M, Greutert H et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005 111 : 1685 9.
50. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005 112 : 759 70.
51. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284 : 1247 55.
52. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med. 2005 165 : 161 8.
53. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000 343 : 1520 8, 2 p following 1528.
54. Walter MF, Jacob RF, Day CA et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004 177 : 235 43.
55. Csiki I, Morrow JD, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin. Cancer Res. 2005 11 : 6634 40.
56. Gasparini G, Meo S, Comella G et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J. 2005 11 : 209 16.
57. Nugent FW, Mertens WC, Graziano S et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 2005 48 : 267 73.
58. Lipton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology 2004 18 (Suppl. 14 43 5.
59. Reardon DA, Quinn JA, Vredenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005 103 : 329 38.
60. Zhu L, Chow LW, Loo WT, Guan XY, Toi M. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin. Cancer Res. 2004 10 : 4639 44.